SAREPTA THERAPEUTICS, INC. Available-for-sale Securities, Transfers to Trading, Gross Gains
SAREPTA THERAPEUTICS, INC. (SRPT) reported Available-for-sale Securities, Transfers to Trading, Gross Gains of $108.07 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesTransfersToTradingGrossGains · last filed 2021-05-05
- SAREPTA THERAPEUTICS, INC. available-for-sale securities, transfers to trading, gross gains for the quarter ending 2020-12-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. available-for-sale securities, transfers to trading, gross gains for the quarter ending 2020-09-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. available-for-sale securities, transfers to trading, gross gains for the quarter ending 2020-06-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. available-for-sale securities, transfers to trading, gross gains for the quarter ending 2020-03-31 was $108.07M.
- SAREPTA THERAPEUTICS, INC. available-for-sale securities, transfers to trading, gross gains for fiscal 2020 was $108.07M.
| Period end | Available-for-sale Securities, Transfers to Trading, Gross Gains 3 month | Available-for-sale Securities, Transfers to Trading, Gross Gains 6 month | Available-for-sale Securities, Transfers to Trading, Gross Gains 9 month | Available-for-sale Securities, Transfers to Trading, Gross Gains 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 derived: sum of 3 quarters · filed 2021-03-01 | $108.07M 10-K · filed 2021-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $108.07M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $108.07M 10-Q · filed 2020-08-05 | ||
| 2020-03-31 | $108.07M 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |